WANBURY
Back to Balance Sheet
|
WANBURY Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹96 Cr | ₹11 Cr | ₹11 Cr | ₹84 Cr | ₹108 Cr |
What is the latest Total Non-Current Liabilities ratio of WANBURY ?
Year | Total Non-Current Liabilities |
---|---|
Mar2024 | ₹96 Cr |
Mar2023 | ₹11 Cr |
Mar2022 | ₹11 Cr |
Mar2021 | ₹84 Cr |
Mar2020 | ₹108 Cr |
How is Total Non-Current Liabilities of WANBURY Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹96 Cr | 787.48 | |
Mar2023 | ₹11 Cr | 2.34 | |
Mar2022 | ₹11 Cr | -87.49 | |
Mar2021 | ₹84 Cr | -21.63 | |
Mar2020 | ₹108 Cr | - |
Compare Total Non-Current Liabilities of peers of WANBURY
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
WANBURY | ₹921.4 Cr | -0.9% | 21.9% | 98.3% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹446,684.0 Cr | 2.9% | 6.4% | 48.1% | Stock Analytics | |
DIVIS LABORATORIES | ₹155,935.0 Cr | 0.5% | -2.1% | 59.2% | Stock Analytics | |
CIPLA | ₹121,639.0 Cr | 2.3% | 1% | 20.6% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹115,931.0 Cr | 3.5% | 15.7% | 20.3% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹97,876.4 Cr | -0.1% | 2.3% | 41.1% | Stock Analytics |
WANBURY Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
WANBURY | -0.9% |
21.9% |
98.3% |
SENSEX | -0.7% |
-1.6% |
11.1% |
You may also like the below Video Courses